Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VENUS REMEDIES Mar-18 |
MYLAN Dec-18 |
VENUS REMEDIES/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 3,547 | - | |
Low | Rs | 61 | 1,952 | - | |
Sales per share (Unadj.) | Rs | 301.8 | 1,632.0 | - | |
Earnings per share (Unadj.) | Rs | -24.9 | 44.3 | - | |
Cash flow per share (Unadj.) | Rs | 2.5 | 349.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 293.3 | 1,765.5 | - | |
Shares outstanding (eoy) | m | 12.34 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 0.3 | 1.7 | 18.4% | |
Avg P/E ratio | x | -3.8 | 62.0 | -6.1% | |
P/CF ratio (eoy) | x | 36.7 | 7.9 | 467.6% | |
Price / Book Value ratio | x | 0.3 | 1.6 | 20.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 1,154 | 1,414,576 | 0.1% | |
No. of employees | `000 | 0.9 | 35.0 | 2.6% | |
Total wages/salary | Rs m | 393 | 0 | - | |
Avg. sales/employee | Rs Th | 4,026.1 | 23,990.1 | 16.8% | |
Avg. wages/employee | Rs Th | 425.0 | 0 | - | |
Avg. net profit/employee | Rs Th | -331.8 | 651.4 | -50.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,724 | 839,653 | 0.4% | |
Other income | Rs m | 23 | 0 | - | |
Total revenues | Rs m | 3,747 | 839,653 | 0.4% | |
Gross profit | Rs m | 395 | 217,271 | 0.2% | |
Depreciation | Rs m | 338 | 157,216 | 0.2% | |
Interest | Rs m | 354 | 40,384 | 0.9% | |
Profit before tax | Rs m | -275 | 19,671 | -1.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 32 | -3,129 | -1.0% | |
Profit after tax | Rs m | -307 | 22,800 | -1.3% | |
Gross profit margin | % | 10.6 | 25.9 | 41.0% | |
Effective tax rate | % | -11.5 | -15.9 | 72.1% | |
Net profit margin | % | -8.2 | 2.7 | -303.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,638 | 468,862 | 0.6% | |
Current liabilities | Rs m | 2,305 | 341,852 | 0.7% | |
Net working cap to sales | % | 8.9 | 15.1 | 59.1% | |
Current ratio | x | 1.1 | 1.4 | 83.4% | |
Inventory Days | Days | 135 | 84 | 162.1% | |
Debtors Days | Days | 46 | 93 | 49.6% | |
Net fixed assets | Rs m | 4,871 | 162,879 | 3.0% | |
Share capital | Rs m | 123 | 447 | 27.6% | |
Net worth | Rs m | 3,619 | 908,351 | 0.4% | |
Long term debt | Rs m | 1,374 | 980,403 | 0.1% | |
Total assets | Rs m | 7,509 | 2,436,552 | 0.3% | |
Interest coverage | x | 0.2 | 1.5 | 15.0% | |
Debt to equity ratio | x | 0.4 | 1.1 | 35.2% | |
Sales to assets ratio | x | 0.5 | 0.3 | 143.9% | |
Return on assets | % | 0.6 | 2.6 | 24.3% | |
Return on equity | % | -8.5 | 2.5 | -337.8% | |
Return on capital | % | 1.6 | 3.2 | 49.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 514 | 174,480 | 0.3% | |
From Investments | Rs m | -123 | -90,187 | 0.1% | |
From Financial Activity | Rs m | -387 | -81,283 | 0.5% | |
Net Cashflow | Rs m | 4 | 1,445 | 0.3% |
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare VENUS REMEDIES With: ALEMBIC PHARMA TTK HEALTHCARE PFIZER AJANTA PHARMA DISHMAN PHARMA
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 1,148 points, down 2.4% at 47,683 levels.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More